• Gemcitabine HCl: Mechanistic Insights and Assay Precision in

  2026-05-31

  Explore the mechanistic depth of Gemcitabine HCl in DNA replication inhibition and practical guidance for implementing precise, reproducible tumor suppression assays in pancreatic cancer models. This article delivers novel perspectives and actionable insights, grounded in the latest multianimal MRI studies.

• FGFR Inhibition and Chemoresistance: Insights from BGJ 398 a

  2026-05-30

  This article examines a recent study establishing that infigratinib (BGJ 398), a pan-FGFR inhibitor, can restore chemosensitivity in multidrug-resistant tumor cells by targeting ABCB1-mediated drug efflux, a property not shared by PD 173074. The findings provide new mechanistic insights for cancer research on FGFR signaling and multidrug resistance.

• Metformin Hydrochloride in Ossification and Glucose Metaboli

  2026-05-29

  Metformin Hydrochloride (Metformin HCl) is transforming both metabolic and musculoskeletal research by targeting AMPK and Nr4a1/Wnt/β-catenin pathways. This guide offers cutting-edge protocol insights, advanced troubleshooting, and a practical translation of new findings for both in vitro and in vivo models.

• Neuroinflammation Drives Mechanical Allodynia via Piezo2-CGR

  2026-05-29

  Liao et al. uncover a neuroinflammatory mechanism linking trigeminal nerve root compression to mechanical allodynia through a Ca2+-dependent Piezo2-CGRP/SP pathway. Their findings clarify the interplay between ATP-driven signaling and mechanotransduction, providing new molecular targets for understanding and modulating trigeminal neuralgia.

• Troglitazone: PPARγ Agonist Workflows in Cancer and Metaboli

  2026-05-28

  Troglitazone enables precise modulation of PPARγ pathways for both metabolic and oncology research, with recent advances highlighting its utility in anti-tumor macrophage reprogramming. This guide synthesizes optimized protocols, troubleshooting strategies, and fresh insights from the latest SPP1/TAM-targeting breakthroughs.

• Pazopanib (GW-786034): Protocol Optimization in Cancer Resea

  2026-05-28

  Pazopanib (GW-786034) empowers cancer researchers with potent, multi-targeted RTK inhibition for robust angiogenesis and tumor growth suppression. Recent studies highlight its unique efficacy in ATRX-deficient glioma models, making it a cornerstone for precision oncology workflows.

• U-73122 and the PLC Signaling Axis: Deep Mechanistic Insight

  2026-05-27

  Explore how U-73122, a potent phospholipase C inhibitor, enables precise dissection of PLC signaling pathways in cancer and inflammation. This article delivers advanced scientific analysis and unique insights on assay design, protocol parameters, and translational impact.

• MDL 28170: Calpain Inhibitor Workflows for Neuroprotection &

  2026-05-27

  MDL 28170 stands out as a potent, selective calpain inhibitor, uniquely enabling researchers to probe neuroprotection and apoptosis mechanisms with precision. This article translates recent breakthrough findings into actionable protocols and troubleshooting strategies, empowering advanced experimental designs in neurodevelopment, ischemia, and parasitic infection models.

• Low-Affinity Blockade of N-Type Ca Channels by v-Agatoxin-IV

  2026-05-26

  Sidach and Mintz's study redefines the pharmacological distinctions among neuronal calcium channel subtypes by showing that v-Agatoxin-IVA, a spider toxin, incompletely and with low affinity blocks N-type channels at higher concentrations. This nuanced insight impacts experimental strategies for distinguishing calcium channel subtypes and underscores the importance of channel-selective pharmacological tools in neurophysiology research.

• ATRX-Deficient Gliomas: Enhanced Sensitivity to RTK Inhibiti

  2026-05-26

  The referenced study demonstrates that high-grade glioma cells lacking ATRX exhibit pronounced sensitivity to multi-targeted receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors. These findings suggest that ATRX status is a critical determinant of therapeutic response, with practical implications for designing personalized antiangiogenic strategies and interpreting clinical trial outcomes.

• Eltanexor (KPT-8602): Advancing XPO1 Inhibition in Cancer Re

  2026-05-25

  Eltanexor (KPT-8602) delivers high-potency, oral XPO1 inhibition for translational cancer models, offering precise modulation of tumor suppressor pathways with improved tolerability. This article provides actionable workflows, protocol optimization, and troubleshooting strategies for experimental oncology teams leveraging the latest mechanistic insights.

• CCL7+ Macrophages Drive Immunotherapy Resistance in CRC

  2026-05-25

  This study uncovers how CCL7-expressing tumor-associated macrophages foster resistance to PD-L1 blockade in colorectal cancer by modulating immune cell infiltration and metabolic programming. Targeting CCL7 in the tumor microenvironment offers a promising strategy to potentiate immunotherapy efficacy and alter disease progression.

• FGF2-Mediated Resistance to Apoptosis via BCL-2 Upregulation

  2026-05-24

  The referenced study uncovers a non-cell autonomous mechanism where apoptotic stress triggers FGF2 release, leading to MEK-ERK-dependent upregulation of anti-apoptotic BCL-2 proteins in neighboring cells. This process confers transient resistance to apoptosis, with significant implications for cancer therapy, tissue repair, and the design of apoptosis assays.

• HSP90 Inhibition Destabilizes METTL3 to Suppress MYC in CRC

  2026-05-23

  This study uncovers a mechanistic link between HSP90 chaperone activity and the stability of the m6A methyltransferase METTL3 in colorectal cancer. Inhibiting HSP90 with 17-AAG promotes METTL3 degradation, reduces MYC mRNA m6A modification, and suppresses cancer cell phenotypes, suggesting a new therapeutic axis in CRC.

• FLOT1-FOSL2-EphA2 Axis Regulates Microglial Polarization in

  2026-05-22

  This study elucidates the mechanistic role of the FLOT1-FOSL2-EphA2 signaling axis in regulating microglial polarization and neuroinflammation in Alzheimer’s disease. By demonstrating that disrupting this pathway mitigates pro-inflammatory microglial states and improves cognitive outcomes in AD models, it offers a focused target for future therapeutic strategies.

14560 records 1/971 page Next 12345 下5页 Last page